For example, the advent of trastuzumab has dramatically improved survival in human epidermal growth factor receptor 2 (HER2)-positive breast cancer, leading to increasing incidence of brain metastases in patients as they live longer with systemic disease (6). Here, ERBB2 is linked to breast carcinoma.